CN101116669B - 20(r)-人参皂苷组合物及其应用 - Google Patents
20(r)-人参皂苷组合物及其应用 Download PDFInfo
- Publication number
- CN101116669B CN101116669B CN2006100110948A CN200610011094A CN101116669B CN 101116669 B CN101116669 B CN 101116669B CN 2006100110948 A CN2006100110948 A CN 2006100110948A CN 200610011094 A CN200610011094 A CN 200610011094A CN 101116669 B CN101116669 B CN 101116669B
- Authority
- CN
- China
- Prior art keywords
- ginsenoside
- percent
- iii
- gram
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- CKUVNOCSBYYHIS-SUEBGMEDSA-N (2r,3r,4s,5s,6r)-2-[[(3s,5r,8r,9r,10r,12r,13r,14r,17s)-12-hydroxy-17-[(2r)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-SUEBGMEDSA-N 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 31
- 229940079593 drug Drugs 0.000 claims abstract description 19
- UWGVFBVJCVDUPT-UHFFFAOYSA-N Ginsenoside III Chemical compound C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC(=O)C(=C)C)OC1OC(CO)C(O)C(O)C1O UWGVFBVJCVDUPT-UHFFFAOYSA-N 0.000 claims abstract description 16
- IITVYETYQBNPRC-UHFFFAOYSA-N Ginsenoside III Natural products CC(=C)C(=O)CCC(C)(OC1OC(CO)C(O)C(O)C1OC2OC(CO)C(O)C(O)C2O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7O)C(C)(C)C6CCC45C IITVYETYQBNPRC-UHFFFAOYSA-N 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims description 14
- 238000011275 oncology therapy Methods 0.000 claims description 10
- -1 β-D-glucopyranosyl Chemical group 0.000 claims description 5
- 230000036541 health Effects 0.000 abstract description 11
- 238000002512 chemotherapy Methods 0.000 abstract description 7
- 230000009467 reduction Effects 0.000 abstract description 7
- 230000001093 anti-cancer Effects 0.000 abstract description 6
- 230000036039 immunity Effects 0.000 abstract description 4
- RWXIFXNRCLMQCD-CZIWJLDFSA-N (20R)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-CZIWJLDFSA-N 0.000 abstract 1
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 abstract 1
- XIRZPICFRDZXPF-GCIIHGAUSA-N 20(R)-Ginsenoside Rg3 Natural products CC(=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]3[C@@]4(C)CC[C@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O[C@H]6O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]6O)C(C)(C)[C@@H]4[C@@H](O)C[C@@]23C)C XIRZPICFRDZXPF-GCIIHGAUSA-N 0.000 abstract 1
- CKUVNOCSBYYHIS-LGYUXIIVSA-N 20(R)-Ginsenoside Rh2 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CC/C=C(\C)/C)C)CC4)CC2)CC1 CKUVNOCSBYYHIS-LGYUXIIVSA-N 0.000 abstract 1
- 239000000890 drug combination Substances 0.000 abstract 1
- 229930182478 glucoside Natural products 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 206010028980 Neoplasm Diseases 0.000 description 15
- 210000004881 tumor cell Anatomy 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 229940089161 ginsenoside Drugs 0.000 description 10
- 229930182494 ginsenoside Natural products 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 235000001727 glucose Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- UDLBSRQHKWDKQA-UHFFFAOYSA-N acetyl acetate;sulfuric acid Chemical compound OS(O)(=O)=O.CC(=O)OC(C)=O UDLBSRQHKWDKQA-UHFFFAOYSA-N 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002072 distortionless enhancement with polarization transfer spectrum Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 229930182493 triterpene saponin Natural products 0.000 description 3
- 150000003648 triterpenes Chemical class 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000005100 correlation spectroscopy Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 238000000643 oven drying Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 description 1
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000001896 rotating frame Overhauser effect spectroscopy Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002494 tetracaine hydrochloride Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Landscapes
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006100110948A CN101116669B (zh) | 2006-08-02 | 2006-08-02 | 20(r)-人参皂苷组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006100110948A CN101116669B (zh) | 2006-08-02 | 2006-08-02 | 20(r)-人参皂苷组合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101116669A CN101116669A (zh) | 2008-02-06 |
CN101116669B true CN101116669B (zh) | 2010-12-08 |
Family
ID=39053024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006100110948A Expired - Fee Related CN101116669B (zh) | 2006-08-02 | 2006-08-02 | 20(r)-人参皂苷组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101116669B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103908459B (zh) * | 2013-01-09 | 2018-02-02 | 上海中医药大学 | 三七皂苷Ft1的医药用途 |
CN104644654A (zh) * | 2013-11-20 | 2015-05-27 | 富力 | 20(R)-人参皂苷Rg3在制备乳腺增生药物中的应用及其药物 |
CN104814972A (zh) * | 2015-04-16 | 2015-08-05 | 云南普优生物科技有限公司 | 一种含有人参皂苷的药物组合物 |
CN105832780A (zh) * | 2016-05-25 | 2016-08-10 | 朱国平 | 能增强人体免疫力且具有抗癌作用的药物组合物及其制备方法 |
US11000537B2 (en) * | 2018-10-17 | 2021-05-11 | Amorepacific Corporation | Composition comprising novel ginsenoside |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1425381A (zh) * | 2002-12-28 | 2003-06-25 | 杨淑玲 | 人参皂苷单体配伍治疗癌症的产品 |
-
2006
- 2006-08-02 CN CN2006100110948A patent/CN101116669B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1425381A (zh) * | 2002-12-28 | 2003-06-25 | 杨淑玲 | 人参皂苷单体配伍治疗癌症的产品 |
Non-Patent Citations (4)
Title |
---|
Qiu Feng etc..A new dammarane glycoside |
Qiu, Feng etc..A new dammarane glycoside, ginsenoside III fromtheflower-buds of Panax ginseng C.A. Meyer.CA131:308837.2002, * |
封颖璐等.人参皂苷与肿瘤.国外医学肿瘤学分册32 9.2005,32(9),665-668. |
封颖璐等.人参皂苷与肿瘤.国外医学肿瘤学分册32 9.2005,32(9),665-668. * |
Also Published As
Publication number | Publication date |
---|---|
CN101116669A (zh) | 2008-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yun et al. | Anticarcinogenic effect of Panax ginseng CA Meyer and identification of active compounds. | |
Cham et al. | Solasodine glycosides. Selective cytotoxicity for cancer cells and inhibition of cytotoxicity by rhamnose in mice with sarcoma 180 | |
CN101116669B (zh) | 20(r)-人参皂苷组合物及其应用 | |
CN106967147B (zh) | C27螺甾烷型甾体皂苷化合物与其药物组合物和其应用 | |
CN100473661C (zh) | 达玛烷皂苷配基,它们作为抗癌剂的应用和生产它们的方法 | |
JP6389958B2 (ja) | 瓦草5環性トリテルペンサポニン類化合物抗腫瘍の薬物用途 | |
WO2006063515A1 (fr) | Utilisation de radix sanguisorbae et de son extrait pour la preparation d’un medicament visant a accroitre la numeration erythrocytaire et le taux d’hemoglobine | |
TWI280881B (en) | Use of hederagenin 3-O-alpha-L-rhamnopyranosyl((1->2)-[beta-D-glucopyranosyl(1->4)]-alpha-L-arabinopyranoside or an extract from pulsatillae radix containing the same as a therapeutic agent for solid tumors | |
CN102526146B (zh) | 含有人参皂苷和斑蝥素的药物组合物及其用途 | |
CN101428033B (zh) | 一种混合构型人参皂苷Rh2及其应用 | |
CN102617698B (zh) | 一种制备纤细薯蓣皂苷的方法及其用途 | |
CN106083972B (zh) | 一种罗汉果醇衍生物单体 | |
CN106866776A (zh) | 新型的甾体皂苷类化合物及其应用 | |
CN107383147A (zh) | 一种β‑谷甾醇与依帕司他偶联物及其制备方法和用途 | |
CN102408464A (zh) | 一种新的降三萜类皂苷化合物及其制备方法和用途 | |
CN101948453B (zh) | Neo-克罗烷型二萜化合物及其应用 | |
CN105777854A (zh) | 硫酸依替米星的药物组合物及其在生物医药中的应用 | |
CN103232518B (zh) | 一种新海蓬子降三萜类皂苷化合物及其制备方法和用途 | |
CN100429217C (zh) | 白首乌皂苷化合物、总皂苷及其在治疗胃肠道疾病药物中的应用 | |
CN105963307B (zh) | 一种罗汉果醇衍生物单体及其组合物的用途 | |
CN101293904B (zh) | 一种新的化合物及其制备方法和用途 | |
CN100571726C (zh) | 一种药物组合物 | |
CN105153268A (zh) | 螺甾皂苷类化合物及其应用 | |
CN1302797C (zh) | 一种抗肿瘤血管栓塞剂及其制备方法 | |
CN101838296B (zh) | 一种聚炔苷的制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: DIHON PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: KUNING DIANHONG PHARMACEUTICAL CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: 650106 Kunming science and Technology Development Zone, Yunnan Province Road No. 45 Patentee after: Dihon Pharmaceutical Group Co., Ltd. Address before: 650106 No. 45, medical Road, Kunming hi tech Industrial Development Zone, Yunnan, Kunming Patentee before: Kuning Dianhong Pharmaceutical Co., Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: ZHAO JIANGUO Free format text: FORMER OWNER: DIHON PHARMACEUTICAL GROUP CO., LTD. Effective date: 20140814 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 650106 KUNMING, YUNNAN PROVINCE TO: 650000 KUNMING, YUNNAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140814 Address after: 650000, Kunming District, Yunnan, Wuhua province news Road, community 1, 2, unit 701 Patentee after: Zhao Jianguo Address before: 650106 Kunming science and Technology Development Zone, Yunnan Province Road No. 45 Patentee before: Dihon Pharmaceutical Group Co., Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: DIHON PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER OWNER: ZHAO JIANGUO Effective date: 20141022 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 650000 KUNMING, YUNNAN PROVINCE TO: 650106 KUNMING, YUNNAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20141022 Address after: 650106 Kunming science and Technology Development Zone, Yunnan Province Road No. 45 Patentee after: Dihon Pharmaceutical Group Co., Ltd. Address before: 650000, Kunming District, Yunnan, Wuhua province news Road, community 1, 2, unit 701 Patentee before: Zhao Jianguo |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101208 Termination date: 20190802 |
|
CF01 | Termination of patent right due to non-payment of annual fee |